MaxCyte and VectorBuilder partner to build platform for ex-vivo cell therapies
By
Millie Hoe
8d agoen
Source
bioprocessintl.comMaxCyte and VectorBuilder partner to build platform for ex-vivo cell therapiesbioprocessintl.comThe technology will focus on non-viral delivery methods for cell and gene therapies.
You might also wanna read

CZI and NVIDIA Accelerate Virtual Cell Model Development for Scientific Discovery
Chan Zuckerberg Initiative·8mo ago

CZI and NVIDIA Accelerate Virtual Cell Model Development for Scientific Discovery
Chan Zuckerberg Initiative·8mo ago
Next-generation immune models: bioinks, 3D bioprinting, and future directions
cell.com·1mo ago

Extracellular Vesicles as Anti-Aging Therapeutics: Mechanisms, Bioengineering, and Clinical Perspectives
This comprehensive review article systematically examines the anti-aging potential of extracellular vesicles (EVs), focusing on their multif

Magnetic mixer improves 3D bioprinting
MIT·4mo ago
Protuoso Biosciences raises $9.5M for AI-designed multifunctional biologic drugs
Protuoso Biosciences, a California-based startup, has raised $9.5 million to advance its AI-designed multifunctional biologics platform. The
longevity.technology·1mo agoChina creates new regulatory pathway to accelerate access to advanced biomedical therapies
China has established a new regulatory "tech track" for advanced therapies like personalized cancer treatments, cell and gene therapies, and

Comments
Sign in to join the conversation.
No comments yet. Be the first.